Physician
Ars Treatment Centers, P.C.
Ars Treatment Centers, P.C. was paid $73.26M by Medicaid between Jul 2019 and Dec 2024, across 17 billing codes. Its largest line is G9012, Other specified case management service not elsewhere classified — 63% of everything it billed.
33Billing provider infoARS TREATMENT CENTERS, P.C.
UNIONTOWN, PA 15401
UNIONTOWN, PA 15401
33aNPI1346731171assigned 05/29/2018
33bProvider typeAnesthesiology Physician
28Total paid$73.26M
24GClaims743,115
24DCodes billed17
24AFirst – last monthJul 2019 – Dec 2024
Compared with peers
Next to other Anesthesiology Physician providers in Pennsylvania
Rank by total paid#2 of 168
Median peer was paid$9K
This provider vs. median7,766×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCCORMAC, RUPERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 89 | $136.60 | |
| 2020 | 24,792 | $1.27M | |
| 2021 | 161,349 | $17.74M | |
| 2022 | 161,175 | $17.56M | |
| 2023 | 199,172 | $18.13M | |
| 2024incomplete | 196,538 | $18.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G9012 | Other specified case management service not elsewhere classified | 63% | 186,745 | 179,991 | $46.18M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9.2% | 140,555 | 117,310 | $6.75M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.3% | 166,144 | 142,094 | $6.08M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 4.2% | 32,950 | 24,023 | $3.07M |
| 99340 | 3.8% | 21,719 | 21,394 | $2.79M | |
| 80305 | 3.6% | 108,918 | 92,800 | $2.63M | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.6% | 32,846 | 28,127 | $1.89M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.5% | 31,464 | 28,519 | $1.85M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 2.3% | 10,165 | 9,170 | $1.65M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 2,119 | 2,086 | $150K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 1,756 | 1,709 | $84K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,102 | 4,617 | $65K |
5 more codes
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 357 | $45K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 981 | $23K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 123 | $3K |
| 96127 | <1% | 906 | $652.40 | |
| 99406 | <1% | 265 | $117.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCORMAC, RUPERT (CHIEF EXECUTIVE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.